Product Description
HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33298585/)
Mechanisms of Action: BCMA Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Huadong Pharmaceutical Group New Drug Research Institute
Company Location: Asia Pacific
Company Founding Year: 1993
Additional Commercial Interests: Heidelberg Pharma
Clinical Description
Countries in Clinic: Germany, Hungary, Poland, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Multiple Myeloma|Paraproteinemias
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2024-515273-10-00 |
HDP-101-01 | P2 |
Recruiting |
Multiple Myeloma |
2026-05-26 |
2025-05-02 |
Treatments |
|
NCT04879043 |
HDP-101-01 | P2 |
Recruiting |
Paraproteinemias|Multiple Myeloma |
2025-08-01 |
33% |
2024-07-25 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |